Trial · NCT01507831
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Adverse Events (AEs) | Placebo Q2W | Any AE | 82.5 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Alirocumab 150 mg Q2W | Any AE | 81.0 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Placebo Q2W | Any Serious AE | 19.5 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Alirocumab 150 mg Q2W | Any Serious AE | 18.7 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Placebo Q2W | Any AE leading to death | 1.3 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Alirocumab 150 mg Q2W | Any AE leading to death | 0.5 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Placebo Q2W | Any AE leading to treatment discontinuation | 5.8 | percentage of participants | |
| Percentage of Participants Who Experienced Adverse Events (AEs) | Alirocumab 150 mg Q2W | Any AE leading to treatment discontinuation | 7.2 | percentage of participants | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis | Placebo Q2W | 0.8 | Standard Error 1.0 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis | Alirocumab 150 mg Q2W | -61.0 | Standard Error 0.7 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | Placebo Q2W | 0.7 | Standard Error 1.0 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | Alirocumab 150 mg Q2W | -62.8 | Standard Error 0.7 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | Placebo Q2W | 1.5 | Standard Error 1.0 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | Alirocumab 150 mg Q2W | -63.3 | Standard Error 0.7 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis | Placebo Q2W | 1.4 | Standard Error 1.0 | percent change | |
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis | Alirocumab 150 mg Q2W | -64.2 | Standard Error 0.7 | percent change | |
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | Placebo Q2W | 3.5 | Standard Error 1.1 | percent change | |
| Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis | Alirocumab 150 mg Q2W | -57.8 | Standard Error 0.8 | percent change | |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | Placebo Q2W | 1.2 | Standard Error 1.0 | percent change | |
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | Alirocumab 150 mg Q2W | -52.8 | Standard Error 0.7 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01507831/results